Harris County Psychiatric Center, University of Texas Health Science Center at Houston, Houston, Texas.
Department of Psychiatry and Behavioral Sciences, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas.
J Stud Alcohol Drugs. 2019 Mar;80(2):230-235. doi: 10.15288/jsad.2019.80.230.
The use of synthetic cannabinoid (SC) products has become popular in recent years, but data regarding their impact on hospital stays are limited. The impact of SC and cannabis use on hospital length of stay and doses of antipsychotics at discharge was assessed in this study.
The sample consisted of inpatients with discharge diagnoses of bipolar disorder, schizophrenia, or other psychotic disorders. Medical records of patients with self-reported SC use and negative urine drug screens (SC group, n = 77), with cannabis use confirmed by urine drug screen (cannabis group, n = 248), and with no drug use confirmed by urine drug screen (no-drug group, n = 1,336) were examined retrospectively.
Length of stay (mean [SD] days) significantly differed (p < .001) among the SC (8.29 [4.29]), cannabis (8.02 [5.21]), and no-drug groups (10.19 [9.08]). Antipsychotic doses (chlorpromazine milligram equivalent doses) also significantly differed (p = .002) among the SC (254.64 [253.63]), cannabis (219.16 [216.71]), and no-drug groups (294.79 [287.85]). Unadjusted and adjusted pairwise comparisons showed that the cannabis group had a shorter length of stay (p < .001) and received lower doses of antipsychotics (p = .003) than the no-drug group. SC users did not differ significantly from the other two groups in either length of stay or doses of antipsychotics.
Our findings suggest that acute SC exposure is not predictive of a more prolonged time for response to antipsychotic medications or of a need for larger doses of these medications compared with cannabis users.
近年来，合成大麻素（SC）产品的使用变得越来越流行，但关于它们对住院时间影响的数据有限。本研究评估了 SC 和大麻使用对住院时间和出院时抗精神病药物剂量的影响。
样本包括出院诊断为双相情感障碍、精神分裂症或其他精神病性障碍的住院患者。回顾性检查了自我报告 SC 使用且尿液药物检测阴性（SC 组，n = 77）、尿液药物检测阳性证实大麻使用（大麻组，n = 248）和尿液药物检测阴性证实无药物使用（无药物组，n = 1,336）的患者的病历。
住院时间（平均值[标准差]天数）在 SC 组（8.29 [4.29]）、大麻组（8.02 [5.21]）和无药物组（10.19 [9.08]）之间存在显著差异（p <.001）。抗精神病药物剂量（氯丙嗪毫克当量剂量）在 SC 组（254.64 [253.63]）、大麻组（219.16 [216.71]）和无药物组（294.79 [287.85]）之间也存在显著差异（p =.002）。未经调整和调整后的两两比较显示，大麻组的住院时间较短（p <.001），抗精神病药物剂量较低（p =.003），与无药物组相比。与其他两组相比，SC 使用者在住院时间或抗精神病药物剂量方面没有显著差异。
我们的研究结果表明，与大麻使用者相比，急性 SC 暴露并不预示对抗精神病药物反应时间延长或需要更大剂量的这些药物。
